Group items tagged

Moderna has joined one of the UK's leading pharmaceutical industry body, Association of the British Pharmaceutical Industry (ABPI) to expand its footprint and investment in the UK. The biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines will strengthen its footprint with the new state-of-the-art vaccine research, development and manufacturing facility in the UK. It will create valuable new jobs and build on the strength of the UK's life sciences ecosystem. The company is best known for their work during the COVID-19 pandemic and are now developing a range of mRNA-based vaccines for a number of conditions. The ABPI represents companies of all sizes who invest in discovering the medicines of the future, including some of the world's largest, most innovative, and most successful pharmaceutical firms. Darius Hughes, UK General Manager, Moderna, said: "We are delighted to join the ABPI - this alliance is an important part of our long-term commitment to the UK and supports the wider significant investments in manufacturing, research and development we are making in this country.

The UK pharmaceutical industry experienced a substantial increase in public trust and favourability during the Covid-19 pandemic, according to a new poll. This trend appears to be persisting with the study showing a generally favourable view of the sector. The recent survey, conducted by Ipsos and commissioned by Association of the British Pharmaceutical Industry (ABPI), represents the third instalment in a series that began in 2021. This ongoing study targets members of the public, healthcare professionals, and parliamentarians. The study once again underscored a favourable perception of the sector with 67 per cent of respondents recognising that the pharmaceutical industry produces safe and effective medicines using cutting-edge technologies. Moreover, a majority agrees that it is a highly innovative field. Seven out of 10 people also trust the sector's readiness to address future pandemics, even as media attention on pharmaceutical companies returns to pre-pandemic levels. However, concerns arise regarding limitations in accessing new medicines due to cost pressures.

The Royal Pharmaceutical Society (RPS) has confirmed it will respond to UK Commission's 'call for evidence' on pharmacy professional leadership. The commission wants to ensure the professions are well equipped, with a voice to help shape the future, and enabled to develop through sharing and learning from best practice. The UK Commission on Pharmacy Professional Leadership has been set up by the chief pharmaceutical officers of England, Scotland, Wales and Northern Ireland. It will produce recommendations for the future of pharmacy professional leadership in the UK. The commission is co-chaired by Nigel Clarke, former chair of the General Pharmaceutical Council, and Professor Dame Jane Dacre, professor of medical education at University College London's Medical School. The commission will be hosting a webinar and has urged the associations and individuals to take part in 'call for evidence' which has been launched to inform and develop its work. A webinar in England will take place on Wednesday 7 September 6:30 - 8 pm. In Scotland it will be organised on Tuesday 6 September 7-8:30 pm and in Wales it will be hosted on Thursday 8 September 7-8:30 pm.

Aspire Pharma has completed the acquisition of Morningside Pharmaceuticals (Loughborough), Morningside Healthcare (Leicester) and Morningside Healthcare (India); speciality generic pharmaceutical organisations. Morningside delivers Aspire added talent, increased in-market range, and an industry leading pipeline, complementary to Aspire's. "We are excited to welcome the Morningside team to the Aspire family. This is a transformative opportunity for both companies to expand and enhance our market position as a result of both companies highly complementary product portfolios. The combination will create one of the largest and fastest growing UK pharma companies and see further accelerated growth potential in our current and future product portfolio, in the UK and internationally," said Richard Condon, Chief Executive Officer of Aspire Pharma.

DE Group, one of the UK's leading independent pharmaceutical wholesalers, has gone into administration. Pharmacy Business has learnt that the group was put into administration on Monday (May 9), putting hundreds of jobs at risk and stoking fears of a "sudden shock" to pharmaceutical supply chain. A community pharmacy contractor who has done business with the wholesaler for over 20 years told Pharmacy Business: "I fear for the worst. I don't think there will be enough supply of medicines to cope up with a surge at such a short notice." Bharat Shah, founder and CEO of Sigma Pharmaceuticals, another leading short-line wholesaler, said the news will send shock-waves and have "a massive impact on the market" because DE Group enjoyed a "substantial coverage and market share" in the independent pharmacy sector. "It won't be easy for anyone to take on the extra volume as it could jeopardise their own business," he said, adding that Sigma was actively looking into expanding its own operations in the foreseeable future.

The Association of the British Pharmaceutical Industry (ABPI) has issued a challenge to all political parties to outline detailed plans aimed at maximising the industry's role in driving UK health and economic prosperity. In 2022, the pharmaceutical sector invested £9 billion in UK research and development, generating £16.4 billion in economic value and sustaining 126,000 high-skilled jobs nationwide. Ahead of the 2024 general elections, ABPI's Manifesto for Investment, Health, and Growth outlines a strategic framework to enhance patient care within the NHS. It includes expanding access to new medicines through clinical trials and bolstering domestic manufacturing capabilities. It also includes creating additional high-skilled employment opportunities across the UK. As per the association, the potential impact of these initiatives is substantial.

AmerisourceBergen, a leading pharmaceutical solutions organisation announced its intent to change its name to 'Cencora' to better reflect its bold vision and purpose-driven approach to creating healthier futures. Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen said: "Over time, we have established ourselves as a trusted industry partner that prioritizes innovation, advocates for patient access and advances strategic partnerships across the global pharmaceutical supply chain. To further bolster our position, we must continue to adapt and evolve within our dynamic industry as we pursue the goal of enhancing health outcomes. Building a unified brand is fundamental to our identity as a global healthcare company. We believe our new name better reflects who we are today and our impact across pharmaceutical care." AmerisourceBergen intends to begin operating as Cencora in the second half of calendar year 2023. The change to Cencora is aligned with the organisation's growth strategy and continued emphasis on innovation. AmerisourceBergen has focused on supporting pharmaceutical advancement and access for patients, manufacturers, and providers across the global healthcare supply chain.

British Pharma giant, GSK is planning to invest more than £200 million (about $253 million) into the United Kingdom over the next two years to strengthen its manufacturing network. The money will be used to improve the pharmaceutical group's UK sites, including construction of new facilities and assembly lines, The Daily Mail first reported on Sunday. GSK has already earmarked £67 million to upgrade its manufacturing site in Montrose, Scotland, where a new production facility is being constructed. The upgrade is expected to help boost its production of active pharmaceutical ingredients (API) for the future supply of medicines. Regis Simard, head of global supply chain, told the publication that their six UK manufacturing sites, including Montrose, are an important part of their global manufacturing network.

David Webb has been appointed as the new chief pharmaceutical officer (CPO) for England. He will take over from Dr Keith Ridge who steps down next month after serving the role for sixteen year. Webb is currently chief pharmacist and clinical director for pharmacy and medicines optimisation at Guy's and Thomas's NHS Foundation Trust, London. Sharing the news of his appointment on Twitter on Friday afternoon (January 7), he said he was "really delighted and honoured" to be named the CPO for NHS England and that he was as the appointed Chief Pharmaceutical officer for "looking forward to working with pharmacy leaders, colleagues & teams across all sectors from February." He also extended his gratitude to the outgoing CPO for his "outstanding contribution" who, in turn, congratulated Webb and said it was "an honour to be handing over to him". In the same message, Dr Ridge thanked "all the great people I've worked with over the last 16 years for your support, friendship, good humour, great ideas & challenge. I wish you all well for the future."

The Royal Pharmaceutical Society (RPS) has been on the lookout for innovative ideas and suggestions that could transform the future of pharmacy practice in England over the next decade. The society's new project with the King's Fund to transform the future of pharmacy practice in England is at a consultation phase, seeking views and opinions of pharmacy teams from all areas of practice including primary, secondary, social and community care to ensure that the system gets the best out of pharmacy and the public receives seamless, joined-up care. "We want to build a vision that sets out the role of and value of pharmacists and pharmacy teams working across systems, providing patient care and NHS services," said RPS in a statement. "Transforming the future of pharmacy practice recognises the urgent need to build on new ways of working established across health and care systems during the pandemic to meet the increasingly complex health needs of people and improve patient outcomes."

Pharmacy professionals to be included as key stakeholders in the implementation, delivery and evaluation of a wide range of genomic services, said the Royal Pharmaceutical Society (RPS). RPS's statement has been developed in collaboration with pharmacy organisations who have co-badged the report, such as the British Oncology Pharmacy Association, the UK Clinical Pharmacy Association, Association of Pharmacy Technicians and the College of Mental Health Pharmacy. It looks at current and future roles for pharmacy professionals in genomic medicine across many aspects of practice such as person-centred care and collaboration, professional practice, education, leadership, management and research. Pharmacists and pharmacy technicians in the UK have already established roles in the application of genomic medicine in some areas of practice, such as antimicrobial stewardship and infectious diseases, and the management of certain genetic conditions, such as cystic fibrosis. The society believes, the current role of pharmacy professionals in genomics can be expanded upon in the future to both lead and support many relevant aspects of genomic implementation. These are described across all healthcare sectors, within the Genome UK strategy produced by the UK Government, and within the implementation plans published in England, Scotland and Wales. Lead for Pharmacogenomics at RPS Sophie Harding said: "Pharmacy professionals are the gatekeepers of medication safety and efficacy across all areas of healthcare. They are skilled at interpreting complex scientific data and use evidence-based medicine to maximise the benefits of treatments for patients, whilst supporting shared decision-making with patients and the multidisciplinary team.

The UK Commission on Pharmacy Professional Leadership set up by the Chief Pharmaceutical Officers of England, Northern Ireland, Scotland and Wales has published its recommendations for the 'future of pharmacy professional leadership in the UK' on Monday (6 February). The Commission is co-chaired by Nigel Clarke, Former Chair of the General Pharmaceutical Council, and Professor Dame Jane Dacre, Professor of Medical Education at University College London Medical School. The Commission proposes that closer collaboration between professional leadership bodies and specialist professional groups as part of a Pharmacy Leadership Council will enable and support pharmacists and pharmacy technicians to meet the opportunities and challenges ahead. The Council will be set up in 2023 to lead the implementation of the report's vision and recommendations over five years. Commission Co-Chairs, Professor Dame Jane Dacre and Nigel Clarke: "The Commission has set out a collaborative approach to transform pharmacy professional leadership and deliver sustained benefits for patients and the public and pharmacy professionals in the UK.

An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights for Covid-19 interventions between the pharmaceutical industry and developing nations endures. At the heart of the plan is a commitment to set aside part of the production of vaccines and treatments upfront for vulnerable populations in low-income countries when the next pandemic arises, given how fragmented access to Covid tools has left many populations unprotected. In order to do better next time - and without knowing which companies will develop the first drugs and vaccines for the next pandemic - having the industry collectively make this commitment is potentially transformative, said Thomas Cueni, head of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). The pledge, called the Berlin Declaration, was made on July 19 by members of the global pharmaceutical industry group that include many of the companies involved in developing Covid interventions, such as AstraZeneca, GSK, Moderna, Pfizer and Merck. The declaration is not legally binding. However, if a company that signed on reneges on its vow, it would face grave consequences in the court of public opinion, said Cueni.

The Royal Pharmaceutical Society (RPS) has re-joined the International Pharmaceutical Federation (FIP) after reflecting its commitment to international collaboration and the advancement of the pharmacy profession. RPS President Professor Claire Anderson said: "Members told us they wanted to see us re-join FIP to further our commitment to international partnerships which support education and advocacy to develop and progress the pharmacy profession.". "We fully recognise the importance of international collaboration and the sharing of knowledge and best practice with our peers across the world. "FIP are refocusing their membership offer and we're delighted to work with them on opportunities for professional development and increased visibility and recognition for the pharmacy profession." Paul Bennett, RPS CEO said: "Now that we have re-joined, our teams across RPS look forward to reinvigorating the close collaboration we have previously enjoyed with our colleagues both within FIP itself, and across the breadth of FIP Member organisations to further our vision and mission".

The Royal Pharmaceutical Society has stated that the UK Commission on Pharmacy Professional Leadership lacks the essential transparency, efficiency, and diligence needed for success, urging a shift in its approach. The Commission's operational approach hinders its ability to meet the expectations of both the profession and the public, while prioritising government interests over their needs and preferences, RPS Chief Executive Paul Bennett (R) and President Claire Anderson have jointly said. In a blog post on September 7, the RPS leaders asserted that the Commission lacks transparency and is progressing slowly in implementing proposals that were published seven months ago. "Most pharmacy leaders are growing frustrated and increasingly impatient with the Commission's perceived lack of "meaningful progress" in enhancing leadership within the field," the pair noted. In June 2022, the four UK Chief Pharmaceutical Officers (CPhOs) formed an independent Commission with leadership expertise drawn from various domains, both within and outside of pharmacy, to assess the future of professional leadership. The Pharmacy Minister Neil O'Brien recently revealed that the Commission's costs, funded by the offices of the CPhOs, amounted to £87,745.

Pharmaceutical companies AbbVie and Eli Lilly have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday. Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global boardrooms and investors as repayment rates in 2023 have surged to 26.5 per cent of revenue, the Association of the British Pharmaceutical Industry (ABPI) said in a statement. "The current scheme has harmed innovation, with costs spiralling out of control, and the UK falling behind other major countries to be left as a global outlier," said Laura Steele, president and general manager for Eli Lilly's Northern Europe division. ABPI said it was seeking early talks with the government to set out a new future settlement. In December, the industry body had said the government raised the amount manufacturers of branded medicines within the voluntary scheme will be required to return to almost £3.3 billion in sales revenue from an earlier amount of £1.8 billion.

The Pharmacists' Defence Association (PDA) has submitted a 17-page contribution to the commission on the future of pharmacy professional leadership and encourages pharmacists to engage in the overall discussion. The association wants to ensure that the voice of its members is heard in the discussions about the future of professional leadership, which has been initiated by the four government Chief Pharmaceutical Officers. The PDA has published its first formal contribution to the commission, in its response it raised concern on the current exercise is being rushed and a call for the review to be conducted in a more sensible timeframe, one which enables the engagement of the whole profession. It has urged on being supportive of the creation of a Royal College of Pharmacists to take custodianship of the training and education for pharmacists and to set the requisite standards, whilst still relying upon the profession's regulators to undertake the accreditation role.

The Royal Pharmaceutical Society (RPS) is seeking views of pharmacists to help shape the future of pharmacy practice in England over the next decade. The RPS's project with The King's Fund, transforming pharmacy practice, aims to develop a vision for the role of pharmacists and pharmacy teams working across systems, providing patient care and NHS services. It's due to be published at the end of the year. "From 15 August to 30 September we are asking people to respond to our consultation on six key themes," the RPS said. "We'll also be holding face-to-face and virtual events in September to hear your views." The King's Fund has completed a literature review which has helped inform the initial six themes which will be the focus of the consultation, all of which can be downloaded and read before responding.

The National Pharmacy Association (NPA) has announced that the Chief Pharmaceutical Officer for England, David Webb will be among the keynote speakers at the Pharmacy Odyssey Conference on 13 October. He and other special guests will discuss the future of community pharmacy within the NHS, during a day of insight and practical advice for pharmacy teams. The NPA promises expert opinion on the current pressures in the sector and a thorough exploration of the long-term picture. NPA Director of Membership, Simon Tebbutt, explains: "With the NPA centenary in 2021 behind us, this will be a foray into the future - mapping the coming decade, and next half-century - as well as covering the many challenges of the present time." The theme of the conference, to be held online and sponsored by Novo Nordisk, is Pharmacy Odyssey: Services, Supply and Sustainability.

Pharmacy bodies and MPs discussed on support needed to unlock the "full potential" of community pharmacy at the All Pharmacy Party Group (APPG)'s general meeting held in Westminster on Tuesday (01 November). The attendees of the meeting were Janet Morrison OBE, Chief Executive of Pharmaceutical Services Negotiating Committee; Malcolm Harrison, Chief Executive of The Company Chemists' Association; Thorrun Govind, Chair of the Royal Pharmaceutical Society; Sanjeev Panesar, National Pharmacy Association Board Member, and Pharmacist Superintendent and Owner of the Pan Pharmacy Group; and Sandeep Dhami, Association of Independent Multiple Pharmacies member and superintendent at MW Phillips Chemist At the session, 18 parliamentarians were briefed on the myriad of ways pharmacies contribute to the health of the nation. The panel of experts also highlighted that pharmacists are 'running out of fuel' with the growing challenges such as flat funding, workforce shortages and the cost-of-living crisis impacting pharmacies' ability to deliver vital services.